Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Clinical Data in $252 million deal with CombinatoRx to develop novel cancer therapy
September 2009
SHARING OPTIONS:

NEWTON, Mass.Clinical Data Inc. announced in August a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers. Under the agreement, Clinical Data licensed its highly selective adenosine A2A agonist, ATL313, to CombinatoRx in exchange for the potential to receive up to $252 million in clinical, regulatory and commercial milestones, as well as royalties on product sales. CombinatoRx will be responsible for the preclinical and clinical development of ATL313 to potentially treat B-cell malignancies. Clinical Data also retains a co-development option, which is exercisable after review of any Phase IIa study results.          

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.